Drug General Information |
Drug ID |
D0M2XE
|
Former ID |
DAP001093
|
Drug Name |
Insulin-glulisine
|
Indication |
Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]
|
Approved |
[1]
|
Therapeutic Class |
Hypoglycemic Agents
|
Structure |
|
Download
2D MOL
|
Formula |
C258H384N64O78S6
|
CAS Number |
CAS 207748-29-6
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Insulin receptor |
Target Info |
Binder |
[2]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
cGMP-PKG signaling pathway
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
PI3K-Akt signaling pathway
|
AMPK signaling pathway
|
Adherens junction
|
Insulin signaling pathway
|
Ovarian steroidogenesis
|
Type II diabetes mellitus
|
Non-alcoholic fatty liver disease (NAFLD)
|
Aldosterone-regulated sodium reabsorption
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
PI3 kinase pathway
|
Pathway Interaction Database
|
Insulin Pathway
|
Signaling events mediated by PTP1B
|
Signaling events mediated by TCPTP
|
Insulin-mediated glucose transport
|
PathWhiz Pathway
|
Insulin Signalling
|
Leucine Stimulation on Insulin Signaling
|
Reactome
|
IRS activation
|
Signal attenuation
|
Insulin receptor signalling cascade
|
Insulin receptor recycling
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
Insulin Signaling
|
Nanoparticle triggered autophagic cell death
|
AGE/RAGE pathway
|
Signaling by Insulin receptor
|
Folate Metabolism
|
Type II diabetes mellitus
|
Vitamin B12 Metabolism
|
Selenium Micronutrient Network
|
AMPK Signaling
|
References |
REF 1 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. |
---|
REF 2 | Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57. doi: 10.2165/00003495-200969080-00006. |